Tagged with GEN

Switzerland Dr. Othmar Pfannes, founder and CEO of Genedata, a bioinformatics company headquartered in Switzerland delivering enterprise software, data analysis consulting, and business-process analysis services to the life sciences community, reveals some insights into Genedata’s business strategy and how ultimately their mission is to contribute to reducing the costs of drug…

Amgen Established in November 2014, Amgen’s Next-Generation Biomanufacturing facility in Singapore heralds a new juncture of efficient and innovative commercial-scale production of medicines. VP of Singapore Site Operations, Arleen Paulino, pinpoints the elements that distinguish this facility from current standards in manufacturing, while highlighting the key role that this facility will…

Singapore With Amgen having recently reacquired the sales rights to three of its drugs, the company’s GM in Singapore and Malaysia, Raphael Ho, explains the rationale behind Amgen’s recent entry in Singapore and his experience in setting up the affiliate, while also expounding upon the unique value of Amgen products in…

Philippines In an exclusive interview, Kamal Abichandani, Deepu Bhatia, Hersh Abichandani, Richard Mayani, the Chairman, Director, General Manager, and Information Systems Manager of Ambica tell their story and reveal their key to success: quality partnerships. As a former engineer without previous experience in the pharmaceutical industry, what were some of the ambitions that…

Slovakia Genas’ Michaela Palagyi shares the association’s pride in being an affiliate member of Medicines for Europe and how this allows them to liaise more closely with their European counterparts. She also reveals the share of generics in today’s Slovak pharma market: around 60 per cent of volume and slightly less…

Generics Andreas Bosshard of Mepha-Teva in Switzerland describes Switzerland’s unique generics market, the quality of the Mepha-Teva brand, innovations within generics, and the company’s growth strategy within the Swiss market. It has been five years since the merger of Teva and Mepha in Switzerland, and curiously the brand name Mepha remains in…

Pharma MD Natascha Schill discusses the growing importance and commitment that Biogen has to Switzerland, including a USD one billion investment in new facilities and the creation of 400 jobs in the upcoming years; investing in the local workforce to support the company’s growth. The headline-making news at the moment is…

Pharma Teodoro Padilla, Executive Director at the Pharmaceutical and Healthcare Association of the Philippines, and Reiner Gloor, Advisor and Honorary Member, discuss the current objectives and goals of the association, how they are adapting to recent changes in the country’s healthcare landscape, and the impact of the rise of generics. To begin, could…

Pharma The expansion of universal healthcare coverage and significant growth in the use and acceptance of generics across the Philippines pose a significant challenge to the innovative medicines industry but also offers a wealth of opportunities for both international and domestic players. The Philippines now utilizes low-cost generics more than any…

Pharma Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de Elizalde reveals the key pillars that will drive the affiliate to new heights. In Mexico, generics make up 79 percent…

Pharma Dr. Teresa Corona Vázquez, the general director of one of the leading neuroscience institutions in Latin America, details their most important research partnerships and achievements, notably with regards to neurodegenerative diseases, and her expectations of fostering a heightened research-based relationship with the pharmaceutical industry. What have been some of the…

Pharma Axel B. Müller, managing director of Intergenerika, the Swiss generics association, reveals the penetration rate of generics in Switzerland; why generics are a safe, and smarter choice, manufactured to modern standards with affordable prices; and the threat of government forcing generic companies to benchmark their prices to nine European countries…